RxDoctor Payments DataLook up a doctor →

Robert Perry, MD

Internal Medicine · Pembroke Pines, FLNPI 1831245554

Payments from drug & device makers

$9,158,919in general payments, 2019–2025

Across 910 payments — averaging $10,065 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$1.4M
  • Amgen$987K
  • Astrazeneca UK Limited$902K
  • Novartis$818K
  • Eli Lilly$688K
  • H. Lundbeck A S$679K
  • plus $3.7M from 50 others
$20,781in research payments, 2019–2025

Across 8 payments — averaging $2597.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$21K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.9$1,414,795
Amgen11$986,951
Astrazeneca UK Limited5$901,675
Novartis29$817,780
Eli Lilly33$688,432
H. Lundbeck A S21$678,768
Pfizer93$486,080
Astrazeneca AB2$412,227
Boehringer Ingelheim International GmbH108$396,893
AbbVie(2 entities)156$394,306
Bristol Myers Squibb2$359,975
Xeris Pharmaceuticals, Inc.13$355,534
Genentech, Inc.18$354,872
Bavarian Nordic A/s8$241,485
Teva Pharmaceuticals USA, Inc.12$130,275
Emergent Biosolutions Inc.2$125,369
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$94,415
Ardelyx, Inc.6$72,070
Boehringer Ingelheim48$62,874
Merck17$55,892
Eisai Inc.13$54,811
AMAG Pharmaceuticals, Inc.3$22,791
AstraZeneca17$20,818
Regeneron2$13,855
Boehringer Ingelheim Pharma GmbH & Co.kg5$5,082
Boehringer Ingelheim Limited2$3,406
Amarin Pharma, Inc.20$2,639
Novo Nordisk96$1,679
Lilly USA, LLC34$556
Kowa Pharmaceuticals America, Inc.18$411
Takeda Pharmaceuticals U.S.A., Inc.13$262
Radius Health, Inc.13$257
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$247
Sanofi-aventis U.S. LLC13$245
Biohaven Pharmaceuticals, Inc.5$135
Bayer5$110
Cook Medical LLC1$108
Biohaven Pharmaceutical Holding Company Ltd.5$99
Abbott5$98
Verity Pharmaceuticals Inc.4$94
Idorsia Pharmaceuticals US Inc3$72
Regeneron Healthcare Solutions, Inc.2$69
Almatica Pharma LLC3$60
Gilead2$53
Dexcom, Inc.2$47
Viiv Healthcare Company2$46
GSK2$34
Axsome Therapeutics, Inc.1$28
Vivus LLC2$23
Genentech USA, Inc.1$22
Corcept Therapeutics1$18
Johnson & Johnson1$17
Currax Pharmaceuticals LLC1$17
IBSA Pharma Inc.1$16
Astellas Pharma US Inc1$16
Exeltis, USA Inc.1$13

How this compares

$9,158,919 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$97,230
Medicare patients
276
Services billed
822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →